Skip to main content

Infographic: European biotech financing is maturing, but the gap with the United States keeps growing

How much financing is needed to encourage growth in Europe’s biotech sector? The analysis in our latest report, “Biotech in Europe: A strong foundation for growth and innovation,” shows that investment in European biotechs is increasing. In late-stage financing, however, Europe lags behind the United States by a large (and still growing) margin—the US sector receives almost five times as much private funding as its European counterpart does. But overall, European biotechs have been good value for investors, and financing is maturing.
European biotech financing is maturing but the gap with the US keeps growing
We strive to provide individuals with disabilities equal access to our website. If you would like information about this content we will be happy to work with you. Please email us at: McKinsey_Website_Accessibility@mckinsey.com

Related Articles